The business model of The Cigna Group is a sophisticated, multi-layered financial and operational ecosystem designed to manage the profound actuarial and clinical risks of human health while extracting value from the inefficiencies of the United States healthcare and pharmaceutical systems. At its core, the company operates as a fully integrated managed care organization, functioning as the critical financial intermediary between employers, government entities, and individual consumers on one side, and the vast network of healthcare providers and pharmaceutical manufacturers on the other. The primary engine of the company's revenue and operational complexity is divided into two distinct but deeply interconnected segments: Cigna Healthcare and Evernorth Health Services. The Cigna Healthcare segment operates as a traditional health insurer, collecting premiums from its millions of medical members. These premiums are pooled into a massive reservoir of capital, from which the company pays for the medical claims incurred by its members. The fundamental economic metric that dictates the profitability of this segment is the Medical Loss Ratio (MLR), which represents the percentage of premium dollars spent on actual medical claims and healthcare quality improvement activities. By regulation, Cigna must spend a minimum of 80 to 85 percent of its premium revenue on medical care, meaning the gross margin on its insurance products is inherently capped and exceptionally thin. Therefore, the company's financial success in this segment relies entirely on its ability to manage the denominator—the total cost of medical claims—through aggressive care management, network negotiation, and the promotion of value-based care arrangements. By shifting provider reimbursement from traditional fee-for-service models to capitated or bundled payment arrangements, Cigna aligns the financial incentives of the providers with its own, encouraging preventative care and reducing expensive hospital readmissions. However, the traditional pure-payer model, while generating enormous top-line revenue, is increasingly constrained by regulatory caps on MLR and the immense bargaining power of consolidating hospital systems. Recognizing this structural limitation, Cigna has executed a profound strategic evolution through the creation and massive scaling of the Evernorth Health Services segment. Evernorth represents the company's definitive pivot into the direct management of healthcare services, encompassing pharmacy benefit management (PBM) through its wholly-owned subsidiary Express Scripts, specialty pharmacy distribution, and care delivery solutions. The economics of the PBM model are fundamentally different from traditional health insurance. PBMs act as intermediaries between health plans, pharmaceutical manufacturers, and retail pharmacies. They generate revenue through a complex web of mechanisms, including negotiating rebates and discounts from drug manufacturers in exchange for favorable formulary placement, managing pharmacy networks, and utilizing spread pricing—where the PBM charges the health plan more for a drug than it reimburses the pharmacy. Cigna has increasingly moved toward pass-through pricing models, where rebates are passed directly to the client, generating revenue through transparent administrative fees rather than opaque spread margins. This shift has been driven by client demand for transparency and regulatory pressure, but it has also allowed Cigna to capture massive volume in the highly lucrative specialty pharmacy market. Specialty drugs, which include high-cost biologics, oncology treatments, and the rapidly expanding class of GLP-1 weight-loss and diabetes medications, represent the fastest-growing segment of pharmaceutical spending. By internalizing the specialty pharmacy supply chain through Evernorth, Cigna captures the distribution margins and clinical management fees associated with these ultra-expensive medications, creating a massive, high-volume revenue stream. While the top-line revenue of the PBM segment is enormous, the gross margins are relatively thin because a significant portion of the revenue represents the pass-through cost of the drugs themselves. Therefore, the true financial value of Evernorth lies in its ability to generate substantial operating income through administrative fees, clinical program management, and its critical role in suppressing the overall medical cost trends for the Cigna Healthcare insurance segment. The integration of Cigna Healthcare and Evernorth creates a powerful closed-loop ecosystem. By owning both the health plan and the PBM, Cigna can directly align the clinical and financial incentives across the entire care continuum. For example, if a member is prescribed a high-cost specialty drug, Evernorth can manage the prior authorization, ensure the member receives the medication through a specialized clinical protocol, and monitor their adherence. If the medication successfully manages the patient's chronic condition, it prevents expensive hospitalizations and emergency room visits, thereby reducing the medical claims paid out by the Cigna Healthcare insurance segment. This internal alignment allows Cigna to deploy advanced predictive analytics to identify high-risk patients, intervene earlier in the care continuum, and optimize the total cost of care. Geographically and demographically, the company's business model is highly diversified, balancing the high-margin, employer-sponsored commercial book with the high-volume, lower-margin government programs and the massive, fee-based PBM operations. This diversified membership base insulates the company from the cyclical fluctuations of the employer-sponsored market and the political volatility of government healthcare budgets. Ultimately, The Cigna Group business model is a masterclass in scale economics, risk management, and vertical integration. By utilizing its immense size to negotiate favorable reimbursement rates with providers and pharmaceutical manufacturers, deploying advanced analytics to predict and prevent high-cost medical events, and fully integrating its insurance and pharmacy operations, the company has constructed a resilient financial engine capable of generating hundreds of billions in revenue and substantial free cash flow, even amidst the relentless cost pressures and regulatory complexities of the American healthcare landscape.